Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects.

ABSTRACT:

Introduction

Metformin and glucagon-like peptide-1 (GLP-1) agonists are widely used for treating type two diabetes mellitus (T2DM). While recent studies suggest these drugs might modify the gastrointestinal tract (GIT) microbiome, further confirmation is required from human clinical trials.

Materials and methods

Here, we compare, in patients with T2DM, the effects of metformin (n = 18 subjects) and liraglutide (n = 19), a GLP-1 agonist, on their GIT microbiomes over a 42 day period (n = 74 samples) using 16S ribosomal RNA (rRNA) sequencing.

Results

We found that these drugs had markedly different effects on the microbiome composition. At both baseline and Day 42, subjects taking metformin had a significant increase (Baseline a

SUBMITTER: Wang Z 

PROVIDER: S-EPMC6360918 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature